Sleep deprivation attenuates acute ischemic stroke-induced hippocampal neuronal injury via the IL-38/NF-κB axis.

Interleukin- 17A as an Immunomodulatory Cytokine in Animal Health and Diseases: A Systematic Review.

Interaction between IL-23/Th17 immune inflammatory axis and intestinal flora in gastric mucosal atrophy caused by Helicobacter pylori infection in the elderly.

Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer.

HDAC5 mediates the regulation of muscle-derived interleukin 6 on the differentiation of porcine intramuscular pre-adipocytes.

Frequency of Entamoeba gingivalis and trichomonas tenax with hematological and immunological changes among human.

Sinomenine treats Rheumatoid Arthritis by regulating IL-6 Gene Promoter Methylation.

Hyperandrogenaemia and Systemic Low-Grade Inflammation in Normogonadotropic Anovulation: A Prospective Cohort Study.

Early Alzheimer's disease (AD) treatments include donepezil, memantine and sodium oligomannate, but their comparative effects on cognitive decline and neuroinflammation are understudied. This study compares three drugs' validity in improving two aspects in early AD patients. 132 early AD patients from XX Hospital (Jan 2022-Dec 2024) were retrospectively included. After exclusion, 126 patients were divided into 3 groups (42 each): Group A (donepezil), Group B (memantine), Group C (sodium oligomannate). Cognitive function was assessed using the Mini-Mental State Examination (MMSE), the Alzheimer's Disease Assessment Scale--Cognitive Subscale (ADAS-cog), the Activity of Daily Living Scale (ADL), the Montreal Cognitive Assessment Scale (MoCA), levels of inflammatory mediators, including Tumour Necrosis Factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), neuronal marker levels including β-Amyloid (1-42) (Aβ42), Total tau protein (T-tau protein) and adverse reaction incidence. After treatment, compared with Group A, Groups B/C had significantly higher MMSE, ADL, MoCA, Aβ42 (all P<0.05) and lower ADAS-cog, TNF-α, IL-6, IL-8, T-tau (all P<0.05); compared with Group B, Group C had no significant difference in MMSE, ADAS-cog, ADL, MoCA (all P>0.05), but higher Aβ42 and lower TNF-α, IL-6, IL-8, T-tau (all P<0.05); adverse reaction incidence did not differ significantly among the three groups (P>0.05). Memantine and sodium oligomannate outperform donepezil in improving cognitive function and neuroinflammation, with sodium oligomannate suggesting the best effect on neuroinflammation. This study provides a scientific basis for optimizing early AD medication.

Background: Chronic kidney disease (CKD) is a progressive disorder defined by a persistent reduction in glomerular filtration rate below 60 mL/min/1.73 m² for at least three months. Oxidative stress(OS) play key roles in CKD progression and may be aggravated by repeated hemodialysis sessions. Sulfiredoxin-1 (Srx-1) is a recently identified antioxidant protein involved in reversing oxidative damage and regulating redox signaling; however, its clinical relevance in CKD remains unclear. Methods: A total of 140 participants were enrolled, including 100 CKD patients on hemodialysis and 40 healthy controls. Serum levels of Srx-1, kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) were measured using enzyme-linked immunosorbent assay. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) were determined using standard BIOLABO (France) biochemical kits. Results: Compared with healthy controls, CKD patients showed significantly elevated levels of Srx-1, IL-18, KIM-1, and ALP, along with significantly reduced ALT and AST levels. ALT levels increased significantly after hemodialysis compared with pre-dialysis values. Patients receiving twelve dialysis sessions per month exhibited higher Srx-1, IL-18, and KIM-1 levels than those undergoing eight sessions monthly, while ALP levels were lower. No significant differences were observed regarding age, disease duration, or underlying causes between the groups. Conclusion: The findings demonstrate a close relationship between OS inflammation, and dialysis frequency in CKD. Elevated Srx-1 levels with increased dialysis frequency may represent a compensatory antioxidant response to cumulative OS. Nevertheless, Srx-1 may not be a reliable standalone biomarker, emphasizing the need for further large-scale studies to clarify its clinical significance.

The material basis and underlying mechanism of Folium Artemisiae Argyi in warming meridians and alleviating pain in a rat model of cold-dampness stagnation primary dysmenorrhea.

Evaluation of the effectiveness of cerium nanoparticles as a potential adjuvant in veterinary rabies vaccine.

Muscle wasting is frequently observed in critically ill patients, leading to increased rates of complications and mortality, and could be determined by measuring the quadriceps femoris muscle thickness (QFMT). One significant contributing factor is inflammation, with interleukin-6 (IL-6) as one of the important markers. Branched-chain amino acids (BCAAs), especially leucine, enhance muscle protein synthesis, and reduce inflammation. This study examined the effects of high leucine BCAA supplementation on QFMT and IL-6 levels in critically ill patients. This multicentre, double-blind, randomised controlled trial was conducted in two hospitals in Indonesia from December 2023 to May 2024. Recently admitted critically ill patients were randomly assigned to receive 40 g/day of BCAA (19 g/day of leucine, with a ratio of leucine : isoleucine : valine = 2:1:1.2) supplementation, either enterally or partial parenterally, for 10 days, or to a control group. QFMT was measured using an ultrasound (US), and IL-6 serum levels were measured at baseline and day 10. We performed a linear mixed model to analyse the effects of other factors on outcomes. Forty participants were included in this study; most (78 %) were male, median age 49 (21), and had a surgical diagnosis (55 %). Patients in both groups had similar initial QFMT and IL-6 levels. On day 10 of the study, loss of muscle thickness was found to be less prominent in the BCAA than the control group (0 vs. -13 %, p = 0.001), and the BCAA group showed a significant reduction in IL-6 levels than control (-59.1 vs. 126.5 pg/mL, p = 0.012). Supplementing critically ill patients with high leucine BCAA potentially attenuates muscle mass loss and reduces IL-6 levels. NCT06167772.

Effect of conbercept combined with dexamethasone implantation on macular thickness, visual function, retinal perfusion, and inflammatory markers in patients with diabetic macular edema: A prospective controlled study.

To examine the acute effect of gliclazide on exercise performance and recovery of muscle strength in healthy participants. We conducted a randomized, double-blind, placebo-controlled crossover clinical trial in 44 strength-trained men. They were allocated to gliclazide modified release (MR) (90mg, 8h before exercise sessions) or placebo, undergo three consecutive sessions of strength exercise (four sets, 80% of one-repetition maximum [1-RM] of bench press and free squat exercise). We evaluated total volume-load (VL) (#repetitions x 80%1-RM), range of motion (ROM), insulin and glucose levels, creatine kinase MM (CK-MM), lactate dehydrogenase (LDH), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), hemodynamic parameters, perceived muscle soreness and recovery scores. Gliclazide enhanced strength exercise performance with improvements in total VL (bench press 23.3%, p<0.001; squat 23.2%, p<0.001), and improved muscle recovery 24-48h post-exercise: ROM (shoulder 1.1%, p<0.001; knee 1.6%, p=0.004), CK-MM (-13.2%, p<0.001), LDH (-12.8%, p<0.001), TNF-α (-17.4%, p<0.001), IL-6 (-5.3%, p<0.001), muscle soreness (-17.7%, p<0.001) and recovery scores (32.5%, p=0.001). However, hypoglycemia events were observed in 3 participants in the gliclazide group. In conclusion, Gliclazide MR 90mg, 8h before strength exercise, produced ergogenic effects (exercise performance and muscle recovery), although hypoglycemia was observed in 7% of subjects. Registration: "www.clinicaltrials.gov", "NCT04443777" (Primary Completion: 01/08/2020; Study Completion: 31/10/2023).

Mechanic exploration of Yin Jia tablet against chronic salpingitis via the miR-34a-5p-mediated ceRNA network.

Maternal dietary total antioxidant and oxygen radical absorption capacities and cord blood oxidative-inflammatory response in late-onset fetal growth restriction.

A novel strategy based on serum metabolite-mediated interactions between the lung and gut microbiota to investigate the protective effect of Flos Farfarae against chronic bronchitis.

Ferrostatin-1 attenuates sepsis-induced lung injury by inhibiting ferroptosis via activation of the SLC7A11/GSH/GPX4 signaling pathway.

The aim of this study was to evaluate whether the experimental sealers, composed of tricalcium silicate (CaSi) and CaSi supplemented with calcium hypochlorite (CaSi-H), stimulate tissue repair. The tissue response of experimental materials was compared with commercially available materials Bio-C sealer (BC sealer) and BioRoot (BROOT). Polyethylene tubes filled with materials or left empty (controls) were implanted in rats for 7, 15, 30 and 60 days. The number of fibroblasts, mast cells, collagen content, interleukin-10 (IL-10) and fibroblast growth factor-1 (FGF-1) immunoexpression were evaluated. Data were analysed with two-way anova and Tukey's test, and linear regression. The fibroblast-FGF correlation was estimated using the Pearson correlation coefficient. In all groups, the number of fibroblasts and collagen content increased significantly over time. At all-time points, CaSi-H and control groups showed the highest values of fibroblasts, whereas the lowest values were observed in BROOT. At 60 days, no significant differences were detected among CaSi, CaSi-H, BC sealer and controls. At all-time points, the capsules of CaSi and CaSi-H exhibited the highest values of FGF-1 and IL-10 immunoexpression. CaSi and CaSi-H induced the formation of fibrous capsules, indicating that these sealers stimulate connective tissue repair.